Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Industry Opposes Full Annual Price Revisions at LDP Hearing
November 15, 2017
- MHLW Counterfeit Drug Panel Agrees on “Voluntary” Introduction of GDP in Japan
November 14, 2017
- Benralizumab, Olaparib, Keytruda’s Urothelial Carcinoma Use Up for MHLW Panel Review/Report on Nov. 24
November 13, 2017
- Pilot CEA Program: Company Data, Third-Party Re-Analysis Data Show Big Gaps for Some Products
November 13, 2017
- Dispensing of Generics Down Slightly Despite Increase in Generic-Name Prescribing: Chuikyo Survey
November 13, 2017
- Japan, US Agree to Extend Chuikyo’s Industry Hearing Time
November 9, 2017
- 3rd-Party Re-Analysis Now Complete; Chuikyo Discusses Pilot CEA Products Closed Door
November 9, 2017
- Driver Gene-Based Drug Discovery Also Applicable for Early Approval System: MHLW
November 8, 2017
- 3 Japanese Plasma Fraction Product Makers Raise Concerns about Low NHI Prices at MHLW Panel
November 8, 2017
- Sanofi’s Dupilumab, Chugai’s PD-L1, Keytruda’s Lymphoma Use and More Clear MHLW Panel
November 7, 2017
- 3 Chuikyo Subcommittees to Hold Close-Door Debate on Pilot CEA Products Nov. 8
November 7, 2017
- LDP Group Starts Discussions on Drug Pricing Reform, Hears Opinions from JPMA Chief
November 6, 2017
- PMDA’s Review Division Remains in the Red, with Loss of 2-2.5 Billion Yen Expected for Full Year
November 6, 2017
- PMDA Aims to Speed Up Decision-Making, Streamline Operations
November 6, 2017
- MHLW Wants Chuikyo to Consider Measures to Promote Generic-Name Prescribing
November 6, 2017
- MHLW Advisory Panel Backs Nexium’s Pediatric Dosages, Oral Suspension Form
November 6, 2017
- Hefty Hirudoid Prescriptions Now under Scrutiny, Chuikyo Members at Odds over Restrictions
November 6, 2017
- Heads of Medicines Regulatory Agencies Agree to Promote Global Harmonization to Enable Use of Real World Data as Evidence
November 2, 2017
- Payer Rep Calls on Govt to Promote Use of Formularies at Hospitals to Ensure Use of Cheaper Option: Chuikyo
November 2, 2017
- Clinical Research Review System Based on Clinical Research Law to Start at Minimum of 11 Locations: MHLW
November 2, 2017
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…